Dompé farmaceutici Spa and FarmaMondo entered into an exclusive Managed Access Program distribution agreement appointing the FarmaMondo Group as the exclusive partner to make their innovative product Oxervate™ (Cenegermin) available for patients affected by Neurotrophic Keratitis (NK) in Russia and other CIS countries.

The agreement appoints FarmaMondo as the exclusive provider of access for those NK patients with unmet need through a Named Patient Managed Access Program. The possibility to access the therapy shall bring great hope for NK patients and their families in the region.

“We are pleased to be working with FarmaMondo to deliver this innovative treatment to patients with a serious unmet medical need. We believe expanding the distribution of Oxervate will dramatically improve the life of many now living with a highly debilitating disease,” said Eriona Gjinukaj, Chief Operating Officer of Dompé.